Plasma MIR-212-3p as a biomarker for acute right heart failure with pulmonary artery hypertension

Figures

• 

  Figure 1. The expression of miRNAs in plasma between PAH rats with LPS treatment and PAH rats without LPS treatment. (A) Differences in miRNA expression in the plasma between the two groups of rats are shown by a volcano plot. Red dots represent the downregulated miRNAs, and blue dots represent the downregulated miRNAs; (B) Heat map of differentially regulated miRNAs from plasma samples of PAH rats (n=3) and PAH rats treated with LPS (n=3) as identified by microarray. MiRNAs and subjects are hierarchically clustered by Manhattan distance on the y and x axes, respectively. The relative miRNA expression is depicted according to the color scale shown on the right. Blue and red indicate fold changes as low and high, respectively. PAH, PAH rats; PAH+LPS, PAH rats treated with LPS.

• 

  Figure 2. Functional and pathway enrichment analysis of predicted target genes. (A) The Venn diagram demonstrates the number of the predicted target genes of detected miRNAs with two databases; (B) GO analysis of target genes of differentially expressed miRNAs; (C) KEGG pathway analysis of target genes of differentially expressed miRNAs. The abscissa is the −Lg P value (−LgP), and the larger the −LgP, the smaller the P value is.

• 

  Figure 3. Plasma levels of MiR-212-3p and MiR-29a-3p in PAH patients before and after surgery. (A) Plasma levels of MiR-212-3p in PAH patients before and after surgery; (B) Plasma levels of MiR-29a-3p in PAH patients before and after surgery. Left, n=15; middle, n=12; right, n=3.

• 

  Figure 4. Receiver operating characteristic (ROC) curves were drawn with the fold change data of plasma MiR-212-3p from 15 PAH patients. The AUC curve of MiR-212-3p is was 0.751. The dashed line indicates the “random guess” diagonal line. AUC indicates area under the curve.